American Society of Hematology

Figure 1

$Figure 1. Egfl7 mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.$

Egfl7 mRNA and protein expression in Tie2-Egfl7 transgenic embryos. (A) Schematic organization of Tie2-Egfl7 transgene construct used to generate mice that overexpress Egfl7. (B) Average Egfl7, CD31, and miR126 expression in whole embryos at E12.5, as measured by quantitative RT-PCR. The levels of Egfl7 were normalized to endothelial cell number using CD31 expression. Values are represented as fold difference relative to wild-type: WT, n = 6; TG, n = 4. *P < .01. (C) Detection of EGFL7 and β-tubulin protein in cytosolic fraction isolated from wild-type and transgenic embryos at E12.5. Quantification of protein levels is shown in the graph, and values are made relative to wild-type expression level. White bar represents wild-type; and black bars, transgenic. A vertical line has been inserted to indicate a repositioned gel lane.

This Feature Is Available To Subscribers Only